Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07346157RecruitingPhase 1/Phase 2
Testing a thyroid hormone drug with chemo for relapsed medulloblastoma
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
San Francisco, CaliforniaAges 1–25 - NCT07504796RecruitingPhase 2
Adding ipilimumab to standard melanoma therapy based on ctDNA
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
New York, New YorkAges 18 years+ - NCT07775950Recruiting
Monitoring and treating colorectal cancer based on tumor DNA
This study looks at using a blood test to find cancer DNA and guide treatment for people with stage IV colorectal cancer that has a specific genetic pattern. The goal is to see if this approach can help monitor the cancer and personalize treatment.
Guangzhou, GuangdongAges 18 years+ - NCT05701306RecruitingPhase 1/Phase 2
Study of APG-115 alone or with APG-2575 for certain childhood and adult cancers
This study tests two experimental drugs for people with neuroblastoma or other solid tumors that have not responded to standard treatment. APG-115 is given alone or with APG-2575 to see if it can shrink tumors and help patients feel better.
Guangzhou, GuangdongAges 5 years+ - NCT05594368RecruitingPhase 1
Test targeted radiation to treat recurrent ventricular tachycardia
This trial studies a radiation approach (called stereotactic body radiation therapy, or SBRT) to treat ventricular tachycardia (a dangerous heart rhythm) that keeps coming back. It aims to reduce the rhythm episodes in people who have already tried catheter ablation (a procedure to cauterize rhythm sources) or cannot have it.
OstravaAges 18 years+ - NCT07705035RecruitingPhase 1
DBC-664 for adults with advanced solid tumors
This trial tests a new drug called DBC-664 for people with solid tumors that have come back or spread and cannot be removed by surgery. It may be an option if you have tried other treatments or if standard options are limited.
Denver, ColoradoAges 18 years+ - NCT07775976Enrolling by invitation
Whole-heart checkup with a wearable heart monitor
This study looks at how well a wearable heart monitor and special software can check the health of your whole heart and assess your risk of future heart problems. It may help doctors create more personalized care plans.
Pasadena, CaliforniaAges 18 years+ - NCT05263284RecruitingPhase 1
Study of 8-chloroadenosine plus venetoclax for relapsed or refractory AML
This trial tests a combination of two drugs, 8-chloroadenosine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to prior treatments. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT06399640RecruitingPhase 1
Eltanexor and venetoclax for blood cancers
This trial tests a combination of two oral drugs, eltanexor and venetoclax, for people with certain types of blood cancer that have come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
Memphis, TennesseeAges 18 years+ - NCT07774533RecruitingEarly Phase 1
Imaging osteosarcoma with a new PET tracer
This trial tests a new PET imaging tracer that may help see osteosarcoma tumors more clearly. It is for people whose osteosarcoma has not improved or has returned after standard treatment.
Beijing, Beijing MunicipalityAges 10–80 - NCT05723926Recruiting
Carotid implants to help prevent stroke repeat in atrial fibrillation
This trial tests whether placing a carotid implant can reduce the chance of having another stroke in people with atrial fibrillation who are already taking blood thinners. It aims to prevent stroke recurrence while you continue prescribed anticoagulation.
Rockford, IllinoisAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Chandler, ArizonaAges 18 years+ - NCT07214311RecruitingPhase 2/Phase 3
A trial of PLG0206 to prevent knee joint infection after surgery
This trial tests if a new drug called PLG0206 can stop a knee joint infection from coming back after a surgery called DAIR. DAIR cleans the infected area and keeps the artificial knee in place, and this study wants to see if adding PLG0206 helps prevent the infection from returning.
Sarasota, FloridaAges 18–80 - NCT06246916RecruitingPhase 3
Testing a new immunotherapy combo for advanced melanoma
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Chandler, ArizonaAges 18 years+ - NCT05945732Recruiting
Testing T-DXd or chemo for HER2-low or HR-positive breast cancer
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
GrazAges 18 years+ - NCT04903795RecruitingPhase 1
Testing a targeted immune therapy for EGFR-mutant glioblastoma
This Phase 1 trial tests BRiTE, a custom immune “match” therapy designed to attack glioblastoma cells that have a specific EGFRvIII change. It’s for adults with newly diagnosed or recurring grade 4 glioblastoma, aiming to see safety and whether the treatment can shrink or control tumors.
Durham, North CarolinaAges 18 years+ - NCT07139990RecruitingPhase 1
Personalized radiotherapy for lung, brain, sarcoma, or head and neck cancers
This trial tests whether giving personalized radiotherapy alongside standard treatments can better control several types of cancer: small cell lung cancer, brain metastases, soft tissue sarcoma, and head and neck cancer. It aims to see if this approach helps patients live longer without their cancer growing or coming back.
Dallas, TexasAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant vs standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
Daphne, AlabamaAges 18 years+ - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Mobile, AlabamaAges 18 years+ - NCT06843447RecruitingPhase 1/Phase 2
Study of Raludotatug Deruxtecan for Ovarian Cancer
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
New Haven, ConnecticutAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Mobile, AlabamaAges 18 years+ - NCT06186401RecruitingPhase 1
Experimental immune cell therapy for a specific type of brain cancer
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT06622005RecruitingPhase 1
Combination treatment for multiple myeloma that has returned
This trial tests a new drug (SX-682) added to a standard three-drug combination (carfilzomib, daratumumab, and dexamethasone) for people whose multiple myeloma has come back or stopped responding to previous treatment. The goal is to see if adding this drug helps control the cancer better.
Buffalo, New YorkAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,384 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.